Astellas Pharma (Astellas Pharma) Total Liabilities : $12,956 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Total Liabilities?

Astellas Pharma's Total Liabilities for the quarter that ended in Dec. 2023 was $12,956 Mil.

Astellas Pharma's quarterly Total Liabilities increased from Jun. 2023 ($8,627.32 Mil) to Sep. 2023 ($12,876.16 Mil) and increased from Sep. 2023 ($12,876.16 Mil) to Dec. 2023 ($12,956.02 Mil).

Astellas Pharma's annual Total Liabilities declined from Mar. 2021 ($8,164.86 Mil) to Mar. 2022 ($7,354.58 Mil) and declined from Mar. 2022 ($7,354.58 Mil) to Mar. 2023 ($7,096.61 Mil).

Astellas Pharma Total Liabilities Historical Data

The historical data trend for Astellas Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Total Liabilities Chart

Astellas Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Liabilities

Get a 7-Day Free Trial

5,751.55

9,529.37

8,164.86

7,354.58

7,096.61

Astellas Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															6,993.48	7,096.61	8,627.32	12,876.16	12,956.02

Astellas Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Astellas Pharma's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5431.772	+	(0	+	1479.168
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	185.674)
	=	7,097

Total Liabilities	=	Total Assets (A: Mar. 2023 )	-	Total Equity (A: Mar. 2023 )
	=	18378.266	-	11281.651
	=	7,097

Astellas Pharma's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8012.939	+	(3221.275	+	1537.545
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	184.26)
	=	12,956

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	23396.631	-	10440.612
	=	12,956

Astellas Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma (Astellas Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ALPMF:USA 4503:Mexico 4503:Japan YPHA:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.